Michaël Hocquemiller, PhD Scientific Director, Lysogene Michaël Hocquemiller is scientific director at Lysogene. He has 10 years of experience in research and drug development in the biotechnology industry, focused on neurodegenerative diseases. Dr. Hocquemiller has co-led the Phase 1 clinical trial in MPS IIIA, as well as designing drug candidates and [...]
About bsbhThis author has not yet filled in any details.
So far bsbh has created 199 blog entries.
Samantha Parker Chief Patient Officer Lysogene Samantha Parker is Chief Patient Officer at Lysogene, with more than 20 years’ experience in the pharmaceutical industry: executive and management, strategic leadership, vice president of a foundation for independent professional education in rare diseases, global drug development & patient access across several rare disease [...]
Gabriele Proetzel, Ph.D. Director, Regenerative Medicine, Takeda Gabriele Proetzel, PhD is Director of Regenerative Medicine at Takeda Pharmaceuticals, based in Cambridge, MA. In her current role she is focused on cell and gene therapy therapeutic approaches and strategic alliance management. Prior industry appointments were Chief Scientific Officer at Scil Proteins, Halle Germany, [...]
Dr Christian K Schneider Director of National Institute for Biological Standards and Control (NIBSC) Dr Christian Schneider joined the National Institute for Biological Standards and Control (NIBSC) in January 2016, taking over as Director in April 2016. NIBSC is a centre of the Medicines and Healthcare products Regulatory Agency (MHRA). Christian is [...]
Lord James O'Shaughnessy Parliamentary Under Secretary of State for Health (Lords), UK Government Lord O’Shaughnessy was appointed as a Parliamentary Under Secretary of State at the Department of Health and a Government Whip (Lord in Waiting) in December 2016. Lord O’Shaughnessy was a senior fellow at the Legatum Institute and at [...]
Karen Hodgkin COO, Chief Operating Officer, Cell Medica Karen has over 30 years of experience in planning and running clinical trials. After joining Cell Medica in early 2008 to lead the Clinical Operations and Regulatory functions, Karen moved to become Cell Medica’s COO in September 2016. In the past, Karen has worked [...]
Professor Peter Goodfellow FMedSci FRS, Scientific Advisor, Abingworth Peter Goodfellow is a geneticist who tracked down the genetic essence of human ‘maleness’. In a high-profile scientific race to find the enigmatic ‘testis-determining factor’ (TDF; also known as sex-determining region Y (SRY) protein), Peter overturned others’ claims by correctly pinpointing the tiny SRY [...]
Dr Michael Stein, Chairman and CEO Oxstem Ltd. Dr Michael Stein is a successful healthcare entrepreneur with a background in medical science. In 2001, he co-founded the Map of Medicine Ltd (“the Map”) with University College London. The Map was nationally licensed across NHS England (2005-15) and is today primarily used [...]
Ian Campbell Director for Health and Life Sciences, Innovate UK Dr Ian Campbell is an experienced executive in the life sciences. Ian joined Innovate UK in October 2016 as Director for Health and Life Sciences. Prior to that, he most recently served as Chief Executive of Arquer Diagnostics, a company developing and commercialising immunoassay [...]
Karen Aiach Founder, Chief Executive Officer, Lysogene Founder and CEO of Lysogene, Ms. Aiach is also the mother of a child with MPS IIIA. She has a strong business background starting her career with Arthur Andersen specializing in audit and transaction services. Her entrepreneurial experience includes founding and running a financial business consultancy. [...]